The CERENAT study, another case–control study conducted in multiple areas in France from 2004 to 2006 using data collected in face-to-face interviews using standardized questionnaires (18). This study found no association for either gliomas or meningiomas when comparing regular cell phone users with non-users. However, the heaviest users had significantly increased risks of both gliomas and meningiomas.
In March, however, a peer-review panel of 11 experts from industry and academia voted to advise the agency that it should raise the confidence level from “equivocal evidence” to “some evidence” of a link between cellphone radiation and brain tumors in male rats. (The female rats did not show evidence of a link between the radiation and such tumors.) Two panel members, Lydia Andrews-Jones of Allergan and Susan Felter of Procter & Gamble, proposed the risk upgrade.